Bicara Therapeutics' stock surged 5.68% during intraday trading on Monday, following the company's announcement of significant clinical progress and its fourth quarter and full year 2025 financial results.

The biopharmaceutical company initiated Phase 3 of its FORTIFI-HN01 pivotal trial for ficerafusp alfa, its lead asset targeting first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma. The company also reported its quarterly earnings, with a net loss of $37.4 million for Q4 2025, which met analyst expectations.

Investors responded positively to the clinical milestone, as the Phase 3 trial represents a critical step toward potential regulatory approval. The company's business update highlighted momentum across clinical, regulatory, and corporate priorities, with CEO Claire Mazumdar stating the company is "well positioned to execute on our milestones" and "deliver meaningful value for patients and shareholders."